These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 16307682

  • 1. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.
    Endimiani A, Brigante G, Bettaccini AA, Luzzaro F, Grossi P, Toniolo AQ.
    BMC Infect Dis; 2005 Nov 24; 5():106. PubMed ID: 16307682
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan.
    Hsieh YC, Chang LY, Huang YC, Lin HC, Huang LM, Hsueh PR.
    Clin Microbiol Infect; 2010 Jul 24; 16(7):973-8. PubMed ID: 19778298
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
    Touyama M, Higa F, Nakasone C, Shinzato T, Akamine M, Haranaga S, Tateyama M, Nakasone I, Yamane N, Fujita J.
    J Antimicrob Chemother; 2006 Dec 24; 58(6):1279-82. PubMed ID: 17056610
    [Abstract] [Full Text] [Related]

  • 5. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
    Jorgensen JH, Weigel LM, Ferraro MJ, Swenson JM, Tenover FC.
    Antimicrob Agents Chemother; 1999 Feb 24; 43(2):329-34. PubMed ID: 9925527
    [Abstract] [Full Text] [Related]

  • 6. [Failure of levofloxacin therapy in two cases of community-acquired pneumonia caused by fluoroquinolone-resistant Streptococcus pneumoniae and complicated with empyema].
    Carlavilla AB, López-Medrano F, Chaves F, Villena V, Echave-Sustaeta J, Aguado JM.
    Enferm Infecc Microbiol Clin; 2005 May 24; 23(5):270-3. PubMed ID: 15899177
    [Abstract] [Full Text] [Related]

  • 7. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia.
    Kays MB, Smith DW, Wack ME, Denys GA.
    Pharmacotherapy; 2002 Mar 24; 22(3):395-9. PubMed ID: 11898897
    [Abstract] [Full Text] [Related]

  • 8. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
    Feldman C.
    J Lab Clin Med; 2004 May 24; 143(5):269-83. PubMed ID: 15122171
    [Abstract] [Full Text] [Related]

  • 9. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia.
    Anderson KB, Tan JS, File TM, DiPersio JR, Willey BM, Low DE.
    Clin Infect Dis; 2003 Aug 01; 37(3):376-81. PubMed ID: 12884162
    [Abstract] [Full Text] [Related]

  • 10. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.
    Urban C, Rahman N, Zhao X, Mariano N, Segal-Maurer S, Drlica K, Rahal JJ.
    J Infect Dis; 2001 Sep 15; 184(6):794-8. PubMed ID: 11517444
    [Abstract] [Full Text] [Related]

  • 11. Selection of a gyrA mutation and treatment failure with gatifloxacin in a patient with Streptococcus pneumoniae with a preexisting parC mutation.
    Kays MB, Zhanel GG, Reimann MA, Jacobi J, Denys GA, Smith DW, Wack MF.
    Pharmacotherapy; 2007 Feb 15; 27(2):221-6. PubMed ID: 17253913
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic options for pneumococcal pneumonia in Turkey.
    Oncu S, Erdem H, Pahsa A.
    Clin Ther; 2005 Jun 15; 27(6):674-83. PubMed ID: 16117975
    [Abstract] [Full Text] [Related]

  • 13. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study.
    Brown SD, Farrell DJ, Morrissey I.
    J Clin Microbiol; 2004 Nov 15; 42(11):4980-7. PubMed ID: 15528684
    [Abstract] [Full Text] [Related]

  • 14. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
    Canton R, Morosini M, Enright MC, Morrissey I.
    J Antimicrob Chemother; 2003 Dec 15; 52(6):944-52. PubMed ID: 14585861
    [Abstract] [Full Text] [Related]

  • 15. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
    Zhang FF, Zhao CJ, Wang H.
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec 15; 36(12):940-4. PubMed ID: 24503427
    [Abstract] [Full Text] [Related]

  • 16. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN, Sader HS, Stilwell MG, Fritsche TR.
    Diagn Microbiol Infect Dis; 2007 May 15; 58(1):1-7. PubMed ID: 17408904
    [Abstract] [Full Text] [Related]

  • 17. Molecular epidemiology of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae in Seville.
    Iraurgui P, Torres MJ, Aznar J.
    Enferm Infecc Microbiol Clin; 2012 Apr 15; 30(4):180-3. PubMed ID: 22365183
    [Abstract] [Full Text] [Related]

  • 18. Comparison of drug sensitivity and genotypes of clinically isolated strains of levofloxacin-resistant Streptococcus pneumoniae obtained from Okinawa Island, the Japanese main island and Hong Kong.
    Sunagawa S, Fujita J, Higa F, Tateyama M, Haranaga S, Nakasone I, Yamane N, Uno T.
    J Antibiot (Tokyo); 2011 Aug 15; 64(8):539-45. PubMed ID: 21587266
    [Abstract] [Full Text] [Related]

  • 19. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
    Carratalá J, Martín-Herrero JE, Mykietiuk A, García-Rey C.
    Clin Microbiol Infect; 2006 May 15; 12 Suppl 3():2-11. PubMed ID: 16669924
    [Abstract] [Full Text] [Related]

  • 20. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
    Louie A, Brown DL, Liu W, Kulawy RW, Deziel MR, Drusano GL.
    Antimicrob Agents Chemother; 2007 Nov 15; 51(11):3988-4000. PubMed ID: 17846144
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.